ABIOMED, Inc. (NASDAQ:ABMD) has earned a consensus rating of “Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $157.50.

ABMD has been the subject of a number of research reports. Morgan Stanley restated an “equal weight” rating and set a $140.00 target price (up previously from $135.00) on shares of ABIOMED in a research report on Monday, July 10th. Zacks Investment Research cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. BidaskClub cut shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Saturday, August 26th. Jefferies Group LLC lifted their target price on shares of ABIOMED from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $160.00 target price (up previously from $145.00) on shares of ABIOMED in a research report on Thursday, July 27th.

In other news, Director Eric A. Md Rose sold 23,018 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $151.09, for a total value of $3,477,789.62. Following the completion of the transaction, the director now owns 24,652 shares of the company’s stock, valued at $3,724,670.68. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Paul Thomas sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the completion of the transaction, the director now directly owns 12,172 shares of the company’s stock, valued at approximately $1,883,130.12. The disclosure for this sale can be found here. In the last three months, insiders sold 50,500 shares of company stock valued at $7,603,342. Company insiders own 7.00% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Northwestern Mutual Investment Management Company LLC raised its position in shares of ABIOMED by 0.4% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 6,978 shares of the medical equipment provider’s stock valued at $874,000 after buying an additional 25 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of ABIOMED by 0.5% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 5,947 shares of the medical equipment provider’s stock valued at $852,000 after buying an additional 32 shares during the last quarter. BB&T Securities LLC raised its position in shares of ABIOMED by 1.0% in the second quarter. BB&T Securities LLC now owns 4,154 shares of the medical equipment provider’s stock valued at $595,000 after buying an additional 43 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of ABIOMED by 1.6% in the second quarter. Teacher Retirement System of Texas now owns 3,294 shares of the medical equipment provider’s stock valued at $472,000 after buying an additional 51 shares during the last quarter. Finally, Capstone Asset Management Co. raised its position in shares of ABIOMED by 1.1% in the second quarter. Capstone Asset Management Co. now owns 6,410 shares of the medical equipment provider’s stock valued at $919,000 after buying an additional 70 shares during the last quarter. 89.84% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Brokerages Set ABIOMED, Inc. (ABMD) Price Target at $157.50” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/15/brokerages-set-abiomed-inc-abmd-price-target-at-157-50.html.

ABIOMED (ABMD) traded down 0.18% during mid-day trading on Tuesday, reaching $158.58. 571,195 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $151.77 and its 200 day moving average is $137.70. ABIOMED has a 1-year low of $95.14 and a 1-year high of $159.80. The stock has a market capitalization of $6.99 billion, a PE ratio of 92.74 and a beta of 0.22.

ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. The company had revenue of $132.47 million during the quarter, compared to analysts’ expectations of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The firm’s quarterly revenue was up 28.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.29 earnings per share. Analysts forecast that ABIOMED will post $2.24 earnings per share for the current fiscal year.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.